Literature DB >> 8795571

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.

Y Kano1, M Akutsu, S Tsunoda, J Ando, J Matsui, K Suzuki, T Ikeda, Y Inoue, K Adachi.   

Abstract

We assessed the cytotoxic interaction between paclitaxel and 5-fluorouracil administered at various schedules against four human carcinoma cell lines, A549, MCF7, PA1 and WiDr. The cells were exposed simultaneously to paclitaxel and to 5-fluorouracil for 24 h or sequentially to one drug for 24 h followed by the other for 24 h, after which they were incubated in drug-free medium for 4 and 3 days respectively. In another experiment, the cells were exposed simultaneously to both agents for 5 days. Cell growth inhibition was determined by MTT reduction assay. The effects of drug combinations at IC80 were analysed by the isobologram. The cytotoxic interaction of paclitaxel and 5-fluorouracil was definitely schedule dependent. Simultaneous exposure to paclitaxel and 5-fluorouracil for 24 h showed mainly subadditive effects in A549, MCF7 and WiDr cell lines, whereas it showed additive effects in PA1 cells. Sequential exposure to paclitaxel followed by 5-fluorouracil showed additive effects in all cell lines. Sequential exposure to 5-fluorouracil followed by paclitaxel showed subadditive effects in A549, MCF7 and PA1 cells. Whereas it showed additive effects in WiDr cells. These findings suggest that maximum cytotoxic effects can be obtained when paclitaxel precedes 5-fluorouracil. Interestingly, the continuous (5-day) exposure to paclitaxel and 5-fluorouracil had additive effects in A549, PA1 and WiDr cells, indicating that the prolonged simultaneous administration of these agents may circumvent the antagonistic interaction produced by short-term simultaneous administration. These findings may be useful in clinical trials of combination chemotherapy with paclitaxel and 5-fluorouracil.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795571      PMCID: PMC2074704          DOI: 10.1038/bjc.1996.425

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Paclitaxel: what schedule? What dose?

Authors:  S G Arbuck
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

2.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

Authors:  M C Wani; H L Taylor; M E Wall; P Coggon; A T McPhail
Journal:  J Am Chem Soc       Date:  1971-05-05       Impact factor: 15.419

3.  Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins.

Authors:  P B Schiff; S B Horwitz
Journal:  Biochemistry       Date:  1981-05-26       Impact factor: 3.162

4.  Taxol-induced polymerization of purified tubulin. Mechanism of action.

Authors:  N Kumar
Journal:  J Biol Chem       Date:  1981-10-25       Impact factor: 5.157

Review 5.  An overview of experience with TAXOL (paclitaxel) in the U.S.A.

Authors:  R C Donehower; E K Rowinsky
Journal:  Cancer Treat Rev       Date:  1993       Impact factor: 12.111

6.  Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

Authors:  W K Murphy; F V Fossella; R J Winn; D M Shin; H E Hynes; H M Gross; E Davilla; J Leimert; H Dhingra; M N Raber
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

7.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

Authors:  N M Lopes; E G Adams; T W Pitts; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Effects of CPT-11 in combination with other anti-cancer agents in culture.

Authors:  Y Kano; K Suzuki; M Akutsu; K Suda; Y Inoue; M Yoshida; S Sakamoto; Y Miura
Journal:  Int J Cancer       Date:  1992-02-20       Impact factor: 7.396

9.  Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.

Authors:  C Aschele; A Sobrero; M A Faderan; J R Bertino
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

10.  Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

Authors:  W H Wilson; S L Berg; G Bryant; R E Wittes; S Bates; A Fojo; S M Steinberg; B R Goldspiel; J Herdt; J O'Shaughnessy
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

View more
  17 in total

1.  Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan.

Authors:  Michiya Kobayashi; Koji Oba; Junichi Sakamoto; Ken Kondo; Naoki Nagata; Takehiro Okabayashi; Tsutomu Namikawa; Kazuhiro Hanazaki
Journal:  Gastric Cancer       Date:  2007-02-23       Impact factor: 7.370

2.  The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.

Authors:  Hirofumi Mukai; Yasuhiro Hagiwara; Kentaro Imi; Hirotsugu Isaka; Kenichi Watanabe; Yutaka Matsuyama
Journal:  Oncology       Date:  2017-08-24       Impact factor: 2.935

Review 3.  Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

4.  Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.

Authors:  Yuji Ueda; Hisakazu Yamagishi; Daisuke Ichikawa; Kazuma Okamoto; Eigo Otsuji; Jun Morii; Kinya Koizumi; Naoki Kakihara; Masataka Shimotsuma; Tetsuro Yamashita; Fumihiro Taniguchi; Hideki Aragane; Hiroshi Nishi; Yoshiki Itokawa; Satoshi Morita; Junichi Sakamoto
Journal:  Gastric Cancer       Date:  2010-09-05       Impact factor: 7.370

5.  S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.

Authors:  Ikuo Takahashi; Yoshihiro Kakeji; Yasunori Emi; Masato Sakurai; Yusuke Yonemura; Yasue Kimura; Yoshihiko Maehara
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

6.  Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC).

Authors:  Yasushi Ono; Mitsunori Hino; Yuka Ueda; Ryoko Kamizuru; Masatoshi Omata; Takashi Uehara; Yosuke Tanaka; Tomoyuki Soma; Shoji Kudoh
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil.

Authors:  Weihu Shang; Jinping Qiao; Chenxin Gu; Wei Yin; Jinglei Du; Wei Wang; Meilin Zhu; Mei Han; Weidong Lu
Journal:  BMC Complement Altern Med       Date:  2011-12-02       Impact factor: 3.659

8.  Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.

Authors:  Wainer Zoli; Paola Ulivi; Anna Tesei; Francesco Fabbri; Marco Rosetti; Roberta Maltoni; Donata Casadei Giunchi; Luca Ricotti; Giovanni Brigliadori; Ivan Vannini; Dino Amadori
Journal:  Breast Cancer Res       Date:  2005-06-22       Impact factor: 6.466

9.  Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel.

Authors:  H L Lin; T Y Liu; C W Wu; C W Chi
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

10.  A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.

Authors:  C Kollmannsberger; D Quietzsch; C Haag; T Lingenfelser; M Schroeder; J T Hartmann; W Baronius; V Hempel; M Clemens; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.